BioLineRx vs Xenetic Biosciences
BLRX and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLRX and XBIO compare
Xenetic Biosciences grew revenue faster over the last twelve months (33.3% versus −95.9% for BioLineRx).
Xenetic Biosciences scores higher on the StockData Score (12 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLRX | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.8M |
| Share price | $1.12 | $1.61 |
| Change, 1 year | −65.3% | −38.1% |
| Change, 5 years | −98.9% | −88.9% |
| Beta (5Y) | 1.56 | 1.14 |
| Employees | 20 | 2 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.2× |
| P/B | – | 0.6× |
| Fair value | – | $4.53 |
| Margin of safety | – | 64.4% |
| Growth | ||
| Revenue growth (TTM) | −95.9% | 33.3% (better) |
| Revenue growth, 5Y average | – | 46.8% |
| Profitability | ||
| Gross margin | 80.5% | – |
| Operating margin | −872% | −81.0% (better) |
| Net margin | – | −75.9% |
| FCF margin | −686% | – |
| Return on equity | – | −47.0% |
| Return on invested capital | −59.7% | – |
| Financial health | ||
| Debt / equity | 0.33 (better) | 0.00 |
| Interest coverage | −8.0× | – |
| Current ratio | 1.20 | 7.43 (better) |
| Altman Z-score | – | −37.70 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 6.5% |
| Held by insiders | 0.39% | 12.2% |
| Short interest, % of float | – | 1.8% |
Go deeper
- BLRX stock overview
- BLRX income statement
- BLRX valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.